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INTRODUCTION
Effective pediatric cancer care programs must encompass ear-
ly detection, and ﬁnancial support for treatment [1] as well as
improvement of pediatric cancer units through well-trained
healthcare professionals, who contribute to the multidisciplinary
team approach. In developing countries childhood cancer is an
emerging challenge; mortality rates are not improving and the
cost of care is increasing [2]. It is anticipated that by 2030, the
developing world will account for 70% of all childhood cancers
[3,4], and the cancer-related mortality rate will be ﬁve per
100,000 children. This ﬁgure approximates to the rate reported
in developed countries during the 1980s [5,6].
Progress in cancer survival rates of children is attributed to
long-term investment in health care infrastructure, and the appli-
cation of disease-speciﬁc and risk-adapted treatment protocols
[7–10]. In the USA, between 1990 and 2004 death rates declined
by 1.3% per year for all neoplasms [11]. In Europe, between
1983–1992 and 1993–1997, the 5-year survival increased from
65% to 75% for all childhood cancers [12]. The World Health
Organization analysis of childhood cancer deaths in America,
Asia, and Oceania, 1970 through 2007 reported that the average
annual percent change in mortality from all childhood cancers in
Mexico was þ0.8% for females and þ1% for males, while in
developed countries was  3% for both [13]; in this country
pediatric cancer is the second most common cause of death
among children aged 1–14 years [14].
Mexico is investing to reach equitable pediatric cancer care
and minimize differences in mortality rates according to the geo-
graphic area of residence. The poorest states have reported the
highest mortality rates [15,16]. Also, children without social se-
curity have a 30% greater risk of delayed diagnosis of cancer
when compared with those without social security [17,18].
To mitigate the burden of pediatric cancer, since 2004, the
Mexican government implemented the Fund for Protection
against Catastrophic Expenditures (FPGC is its acronym in
Background. In 2006, the Mexican government launched the
Fund for Protection Against Catastrophic Expenditures (FPGC) to
support ﬁnancially healthcare of high cost illnesses. This study
aimed at answering the question whether FPGC improved coverage
for cancer care and to measure survival of FPGC afﬁliated children
with cancer. Procedure. A retrospective cohort study (2006–2009)
was conducted in 47 public hospitals. Information of children and
adolescents with cancer was analyzed. The coverage was estimated
in accordance with expected number of incident cases and those
registered at FPGC. The survival was analyzed by using Kaplan–
Meier survival curves and Cox proportional hazards regression
modeling. Results. The study included 3,821 patients. From 2006
to 2009, coverage of new cancer cases increased from 3.3% to
55.3%. Principal diagnoses were acute lymphoblastic leukemia
(ALL, 46.4%), central nervous system (CNS) tumors (8.2%), and
acute myeloid leukemia (AML, 7.4%). The survival rates at
36 months were ALL (50%), AML (30.5%), Hodgkin lymphoma
(74.5%), Non-Hodgkin lymphoma (40.1%), CNS tumors (32.8%),
renal tumors (58.4%), bone tumors (33.4%), retinoblastoma
(59.2%), and other solid tumors (52.6%). The 3-year overall survival
rates varied among the regions; children between the east and
south-southeast had the higher risks (hazard ratio 3.0; 95% CI:
2.3–3.9) and 2.4; 95% CI: 2.0–2.8) of death from disease when
compared with those from the central region. Conclusion. FPGC
has increased coverage of cancer cases. Survival rates were different
throughout the country. It is necessary to evaluate the effectiveness
of this policy to increase access and identify opportunities to reduce
the differences in survival. Pediatr Blood Cancer 2013;60:196–
203.  2012 Wiley Periodicals, Inc.
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(wileyonlinelibrary.com).Spanish), as part of the System of Social Protection for Health
commonly known as ‘‘Seguro Popular.’’ FPGC ﬁnancially sup-
ports health care by pooling the risks of high cost and low-preva-
lence diseases such as cancer, neonatal intensive care and HIV/
AIDS [19,20] to those patients that are not afﬁliated with the
social security.
Before the FPGC was initiated, ﬁnancial support was inade-
quate for children with cancer without social security. Families
would have to assume all costs of care, although some support
could be obtained from non-governmental organizations.
In 2006, FPGC began funding the treatment of children with
acute lymphoblastic leukemia (ALL); in 2008 it extended its
beneﬁts to all types of childhood cancer. The ﬁnancial support
varies according to the type of cancer, ranging from Mx$77,080
(US$5,930) for retinoblastoma to Mx$396,544 (US$30,272) for
acute myeloid leukemia (AML).
By 2009, 47 hospitals of the Ministry of Health (MoH) were
afﬁliated with FPGC. All hospitals that manage children with
cancer must be certiﬁed to receive FPGC funds. This means
that the hospital must have well-trained healthcare professionals,
and the resources needed to provide cancer care. The MoH issues
the clinical protocols for the treatments that children should re-
ceive [21]. The protocols are evidence-based and developed by
experts at the Children’s Oncology Group. These protocols in-
clude laboratory tests for diagnosis and follow-up, medications,
ambulatory, and hospital services. The rationale behind these
rules is that cost is not the only barrier for access; the MoH
included the normative dimension of appropriate capability of
public hospitals to provide care to children with cancer.
The three objectives of the study were to investigate the prog-
ress of FPGC to increase coverage of new patients suffering from
childhood cancer, to describe their sociodemographic, clinical
characteristics, and health outcomes, and to analyze overall
survival.
METHODS
This retrospective cohort study was conducted with data of
the period comprised since the onset of FPGC in 2006 to
September 2009. The study population was children and adoles-
cents with newly diagnosed cancer who were cared for at 47 MoH
hospitals afﬁliated with FPGC. The scientiﬁc review board and
the ethics committee of Hospital Infantil de Mexico Federico
Gomez reviewed and approved the study protocol.
For the purposes of this study, coverage measures the extent to
which the provider satisﬁes the potential need for speciﬁc services
in a given community [22]. To investigate the progress of cover-
age, the estimated number of eligible children and adolescents to
receive care by the MoH was used [23]. The country was divided
into ﬁve geographical regions and its corresponding states: West
(Aguascalientes, Colima, Guanajuato, Jalisco, Michoaca ´n, and
Nayarit) Northwest (Baja California, Baja California Sur, Chihua-
hua, Durango, Sinaloa, and Sonora), Central (Distrito Federal,
Hidalgo, Me ´xico, Morelos, Quere ´taro, and Tlaxcala), East (Coa-
huila, Nuevo Leo ´n, San Luis Potosı ´, Tamaulipas, and Zacatecas),
and Southeast (Campeche, Chiapas, Guerrero, Oaxaca, Puebla,
Quintana Roo, Tabasco, Veracruz, and Yucata ´n). The expected
number of patients for all types of cancer was estimated by
multiplying the number of eligible children to receive care (chil-
dren without social security and cared for by the MoH) by 121.5
per 1,000,000 children/years. This is the age-standardized inci-
dence rate for all types of cancer for individuals aged 0–14 years
reported in Mexico [24]. No incidence rate for individuals 15–19
years was available for Mexican population. The resulting number
was divided by 1,000,000. The amount of new cancer patients
from FPGC registries was identiﬁed, and the proportion of cancer
cases funded in relation to the expected number of cases was
calculated. The proportions were estimated by considering the
number of new cancer patients registered as the numerator and
the expected number of cancer patients as the denominator.
To describe the sociodemographic and clinical characteristics
and analyze the survival experience, the analysis comprised the
registries of the claims made by afﬁliated hospitals to FPGC for
reimbursement, and information from clinical charts. A group of
previously trained nurses visited the hospitals and ﬁlled out the
data collection instrument elaborated ad hoc.
The main variables were divided in four areas: sociodemo-
graphic, children clinical characteristics, abandonment, and surviv-
al. The sociodemographic characteristics included geographical
area of residence, mother’s schooling. The clinical characteristics
of children were: sex, age at diagnosis, previous disease, cancer
type,andrisk group ofcancer according toitsprognosisandstageat
diagnosis, relapse, and adverse events (AE).
The diagnosis grouping was established in accordance with the
Third Edition of the International Classiﬁcation of Childhood Can-
cer [25]. Children with high-risk disease were those suffering from
high-risk ALL (children aged <1o r>10 years, with hyperleuko-
cytosis, primary central nervous system (CNS) inﬁltration, T-cell
immunophenotype, Philadelphia chromosome, t(4;11)(q21;q23),
t(8;14)(q24.1;q32), complex karyotype (more than four abnormali-
ties) low hypodiploidy, near tetraploidy; del 17p; t(11q23) [26][27],
high-risk AML (M0, M1, M2, M4, M5, M6, M7) [28], high-risk
Hodgkin and non-Hodgkin Lymphoma (stages III and IV) [29],
high-risk CNS tumors such as astrocytoma y meduloblastoma
(stages III and IV, and metastatic) [30], and stages III and IV solid
tumors [28]. To be able to classify solid tumors correctly, all hos-
pitals had access to a computed axial tomographer, bone scintigra-
phy, bone marrow biopsy, and lumbar puncture as international
standards recommend.
The AE classiﬁcation was in accordance with the National
Cancer Institute, which organizes AE according to the System
Organ Class groupings and severity grades [31]. AE were regis-
tered when a doctor diagnosed the patient and he/she was admit-
ted. AE appeared after diagnosis, regardless of treatment
provision. Only AE graded between 2 and 5 were recorded.
Abandonment was deﬁned as patients that only had up to two
visits registered in the clinical chart, and without further regis-
tries. Survival was measured from the time of initial diagnosis to
the date of death from any cause or to the last date of follow-up or
last contact.
Statistical Analysis
Descriptive analysis was performed by geographical region.
The proportions for all categorical variables were obtained. The
survival analysis included the 2006–2009 period. The Kaplan–
Meier (KM) method was used to estimate survival curves [32]
and their 95% CI (95% CI). The analysis included hematological
malignancies: ALL, AML, Hodgkin lymphoma, and non-Hodgkin
lymphoma; and solid tumors: CNS, osteosarcoma, Wilms’ tumor,
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cases were those without outcome events before the end of the
study. Patients who died, who abandoned treatment or were lost to
follow-up were considered as an AE. The log-rank test was used
to compare survival curves.
To determine the impact of the program on the survival expe-
rience in terms of geographical region, bivariate analyses were
performed to check for possible confounders. For the multivariate
analysis the Cox proportional hazard regression model was used
[33]. The analysis comprised three multivariate models: all types
of cancer, hematologic (ALL), and solid malignancies (CNS). The
multivariate analyses included adjustment for the following fac-
tors: sex, socioeconomic level (mother’s schooling), previous dis-
ease, age of diagnosis, cancer type, relapse, risk group of cancer,
and AE by grading scale. For the purpose of the multivariate
analysis the referent categories were central region, age 1–4 years
at diagnosis, mother’s high school literacy, patients without AE or
with AE grade 1, and lymphoma for cancer type. The variables
relapse and sex were dichotomized. The multivariate analyses
were performed using the backward procedure with elimination
based on P > 0.05. Hazard ratios with 95% CI were calculated
for all types of cancer, ALL, and CNS tumors. The partial likeli-
hood ratio test served to compare the models.
Graphical examination of the KM survival curves, time-depen-
dent covariates in the Cox proportional hazards model, and a
global test of proportionality with the Schoenfeld and scaled
Schoenfeld residuals assessed the Cox proportional hazards as-
sumption for individual variables. The ﬁnal model comprised the
estimates of the covariates of type of cancer, age of diagnosis,
mother’s schooling, risk group of cancer, treatment relapse, AE,
and sex. All tests were two-tailed and P-values <0.05 were con-
sidered signiﬁcant. The ﬁt of the model was evaluated using the
Cox–Snell residuals. All statistical analyses were performed with
STATA version 10.0.
RESULTS
Data were collected from 47 hospitals, accounting for 4,065
patients. The ﬁnal analysis comprised 3,821 patients with newly
diagnosed cancer and 244 cases who were diagnosed before the
program began and entered during relapse.
Table I demonstrates the progress of coverage of new cancer
patients. The total number of eligible (without social security)
patients to receive care ranged from 25.4 million in 2006 to
24.4 million in 2009. The majority of patients were in the central
and south regions. The number of hospitals varied per region. The
estimates of the expected number of cancer patients demonstrated
that central and south-southeast regions had the highest ﬁgures
(774 and 1,118 in 2009, respectively). The highest increase in
coverage was in the northwest (2.2% in 2006 to 77.7% in 2008),
the lowest in the south-southeast (1.6% in 2006 to 37.8% in
2008).
Table II depicts the main characteristics of the population. In
each of the regions, there was a higher proportion of males
(55.6%). Illiterate mothers and those with primary schooling
accounted for 40% of the sample. The percentages of children
with previous diseases ranged from 1.5% (west) to 5.0% (south);
the group of patients aged 1–4 years had the highest percentage
TABLE I. Progress of Coverage of the Fund for Protection against Catastrophic Expenditures of Children and Adolescents With Newly
Diagnosed Cancer
Years
Regions of the country
Total West Northwest Central East South-southeast
Number of children and adolescents cared for by the MoH
2006 5,660,571 2,263,271 6,572,116 1,350,582 9,563,964 25,410,504
2007 5,562,671 2,248,625 6,519,560 1,343,704 9,450,423 25,124,983
2008 5,448,459 2,215,172 6,427,133 1,327,794 9,320,806 24,739,364
2009 5,348,326 2,197,436 6,373,420 1,319,652 9,198,152 24,436,986
Number of hospitals affiliated with FPGC 12 9 11 4 11 47
Expected number of cases for all types of cancer
2006 688 275 799 164 1,162 3,087
2007 676 273 792 163 1,148 3,053
2008 662 269 781 161 1,132 3,006
2009 650 267 774 160 1,118 2,969
Number of new cancer cases covered by the FPGC
2006 33 6 33 10 19 101
2007 300 181 397 110 347 1,335
2008 378 209 540 107 428 1,662
2009
a 163 111 236 45 168 723
Proportion of cancer cases that FPGC funded with respect
to the expected number
%%%% % %
2006 4.8 2.2 4.1 6.1 1.6 3.3
2007 44.4 66.3 50.1 67.5 30.2 43.7
2008 57.1 77.7 69.1 66.5 37.8 55.3
2009
a 50.1 83.4 60.9 56.2 30.0 48.7
aInformation from the cancer cases who were registered from January to September 2009; the study was conducted from October to
December 2009. FPGC: Fund for Protection against Catastrophic Expenditures; MoH: Ministry of Health.
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West
(n ¼ 874) (%)
Northwest
(n ¼ 507) (%)
Central
(n ¼ 1,206) (%)
East
(n ¼ 272) (%)
South-southeast
(n ¼ 962) (%)
Total
(n ¼ 3,821), n (%)
Female sex 45.4 41.0 43.4 48.2 45.4 1,698 (44.4)
Mother schooling 
Illiterate 6.6 8.3 6.0 2.9 13.5 310 (8.1)
Primary school 35.8 18.5 32.7 19.9 40.0 1,240 (32.5)
Secondary school 20.4 16.0 30.4 31.6 17.3 878 (23.0)
Preparatory school 7.1 9.7 13.5 10.3 6.8 367 (9.6)
High school 2.5 4.5 3.8 6.3 1.9 126 (3.3)
Missing date 27.6 43.0 13.6 29.0 20.6 900 (23.6)
Previous disease  1.5 3.0 2.3 2.2 5.0 110 (2.9)
Age of diagnosis 
<1 year 6.1 7.7 7.5 4.0 4.5 237 (6.2)
1–4 years 32.8 33.5 38.1 34.2 34.3 1,340 (35.1)
5–9 years 28.5 23.5 25.0 24.6 28.8 1,014 (26.5)
10–14 years 22.4 23.3 21.7 20.6 23.0 853 (22.3)
15–19 years 10.2 12.0 7.5 16.5 9.5 377 (9.9)
Type of cancer 
Acute lymphoblastic leukemia 48.3 41.8 46.2 36.4 50.3 1,774 (46.4)
Acute myeloid leukemia 8.9 7.1 6.9 4.4 7.8 284 (7.4)
Hodgkin lymphoma 8.7 6.3 5.4 4.4 7.0 252 (6.6)
Non-Hodgkin lymphoma 5.1 4.3 4.1 6.3 4.8 179 (4.7)
Malignant bone tumors 4.9 4.7 4.6 11.0 6.5 216 (5.7)
Central nervous system tumors 8.5 11.8 7.7 9.9 6.2 314 (8.2)
Renal tumors 3.3 6.1 4.2 5.1 4.2 165 (4.3)
Retinoblastoma 2.6 1.8 7.0 4.8 2.8 157 (4.1)
Other 9.6 16 13.8 17.6 10.4 480 (12.6)
High-risk  66.0 58.2 57.5 47.8 56.5 2,239 (58.6)
West
(n ¼ 866)
Northwest
(n ¼ 500)
Central
(n ¼ 1,204)
East
(n ¼ 272)
South-southeast
(n ¼ 962)
Total
(n ¼ 3,804)
Adverse events (AE)  45.1 40.2 52.5 16.1 45.7 1,707 (44.9)
AE by grading scale (indicators of severity)
Adverse events grade 2 and 3  30.7 33.9 31.8 13.2 33.5 1,181 (30.9)
Adverse events grade 4 and 5  14.1 5.7 20.6 2.9 12.2 526 (13.8)
AE by system organ class groupings
Infections and infestations  17.5 21.5 22.6 7.0 17.5 721 (18.9)
Blood and lymphatic system
disorders 
14.2 8.1 28.7 2.6 17.3 684 (18.0)
Gastrointestinal disorders  9.3 2.4 11.4 1.5 9.1 323 (8.5)
Nervous system disorders  2.3 2.0 2.7 1.5 4.8 113 (3.0)
Respiratory, thoracic and
mediastinal disorders 
2.6 1.0 3.2 1.5 2.9 99 (2.6)
Metabolism and nutrition
disorders 
1.7 1.0 3.6 0.0 2.9 91 (2.4)
Renal and urinary disorders 1.5 0.6 1.2 0.4 2.1 51 (1.3)
Others  10.4 11.6 9.0 3.7 11.4 379 (9.9)
West
(n ¼ 874)
Northwest
(n ¼ 507)
Central
(n ¼ 1,206)
East
(n ¼ 272)
South-southeast
(n ¼ 962)
Total
(n ¼ 3,821)
Health status 
Alive 72.9 67.9 73.4 62.1 58.8 2,601 (68.1)
Dead 22.2 25.6 19.9 17.3 30.7 906 (23.7)
Treatment abandonment 2.1 4.1 4.4 20.2 9.3 237 (6.2)
Missing date 2.9 2.4 2.3 0.4 1.2 78 (2.0)
n, number of children; statistical analysis comprised comparisons among regions, P-value was calculated using x
2-test.  P < 0.05. Previous
disease included congenital anomalies or hereditary diseases (n ¼ 58), anemia (n ¼ 43), chronic infectious diseases like tuberculosis and HIV
(n ¼ 9).
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the most frequent diagnosis (46.4%), followed by CNS tumors
(8.2%), and AML (7.4%); 58.6% was considered high-risk. 44.9%
had AE; 30.9% had AE grades 2 and 3, and 13.8% had AE grades
4 and 5. The most frequent AE were infections and infestations
(18.9%), followed by blood and lymphatic system disorders
(18%). The east region had less AE documented than the other
regions. At the time of data collection, 68.1% of patients were
alive, 23.7% had died, 6.7% had abandoned treatment and 2% had
missing data. The east region showed the highest proportion of
abandonment.
Figure 1A depicts the unadjusted KM survival curves of cases
with hematologic malignancies. The survival estimates considered
up to 36 months of follow-up of new cases. The survival rates
were as follows: ALL 50% (95% CI: 40.3–59), AML 30.5% (95%
CI: 22.8–38.5), Hodgkin lymphoma 74.5% (95% CI: 64.5–82.1),
and non-Hodgkin lymphoma 40.1% (95% CI: 25.1–54.6). The
log-rank test was P < 0.0001.
Figure 1B presents the unadjusted KM survival curves for
children with solid tumors. The survival estimates comprised
36 months after diagnosis: the survival rates of CNS tumors
were 32.8% (95% CI: 19.2–47.1); renal tumors: 58.4% (95%
CI: 43.0–70.9), bone tumors: 33.4% (95% CI: 23.4–43.7); for
retinoblastoma: 59.2% (95% CI: 46.1–70.1), and for other solid
tumors: 52.6% (95% CI: 40.7–63.1). The log-rank test was
P < 0.0001.
Figure 2A displays the estimated survival function of CNS
tumors by region. The unadjusted KM survival curves for the
ﬁve regions demonstrated that patients from the northwest and
south-southeast had lower unadjusted survival estimates than the
other regions. The 3-year survival rates by region were: west
53.8% (95% CI: 33.9–70.1), east 52.3% (95% CI: 28.7–71.5),
center 43.9% (95% CI: 23.2–62.9), northwest 22.1% (95% CI:
4.9–47.0), and south-southeast 8.4% (95% CI: 0.7–29.5). The log-
rank test was P < 0.005.
Figure 2B concentrates on the estimated survival function of
leukemia (ALL and AML) by region. The plots of the unadjusted
KM survival curves for the ﬁve regions are depicted in the same
graph. The KM curve for the south-southeast was consistently
lower than KM curves for other regions. After 12 months, as
the number of follow-up months increased, the KM curves grew
Fig. 1. Estimates of survival for children ﬁnanced by the Fund for
Protection against Catastrophic Expenditures by type of cancer. A:
Children with hematologic malignancies (n ¼ 2,489). The 3-year
survival rates (KM and 95% CI) were: ALL 50% (40.3–59), AML
30.5% (22.8–38.5), Hodgkin lymphoma 74.5% (64.5–82.1), and non-
Hodgkin lymphoma 40.1% (25.1–54.6). Log-rank test, P < 0.0001.
B: Children with solid tumors (n ¼ 1,332). The 3-year survival rates
(KM and 95% CI) were: CNS tumors 32.8% (19.2–47.1), Renal
tumors 58.4% (43.0–70.9), Bone tumors 33.4% (23.4–43.7), Retino-
blastoma 59.2% (46.1–70.1), and others solid tumors 52.6% (40.7–
63.1). Log-rank test, P < 0.0001.
Fig. 2. Estimates of survival for children ﬁnanced by the Fund for
Protection against Catastrophic Expenditures by geographic region.
A: CNS tumors by region (n ¼ 314). The 3-year survival rates (KM
and 95% CI) were: west 53.8% (33.9–70.1), east 52.3% (28.7–71.5),
center 43.9% (23.2–62.9), northwest 22.1% (4.9–47.0), and south-
southeast 8.4% (0.7–29.5). Log-rank test, P < 0.005. B: Leukemia
(ALL and AML, n ¼ 2,048). The 3-year survival rates (KM and 95%
CI) were: west 51.4% (31.1–68.4), northwest 64.6% (55.6–72.2), east
57.7% (49.4–65.1), center 43.4% (22.3–62.8), and south-southeast
21.3% (6.8–41.0). Log-rank test was P < 0.0001.
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geographical region were: west 51.4% (95% CI: 31.1–68.4),
northwest 64.6% (95% CI: 55.6–72.2), east 57.7% (95%
CI:49.4–65.1), center 43.4% (95% CI: 22.3–62.8), and south-
southeast 21.3% (95% CI: 6.8–41.0). This indicates that children
with cancer in the south-southeast region had poorer survival
prognosis than children from the other regions. The log-rank
test was P < 0.0001.
Table III summarizes the Cox proportional hazards model
analyzing the inﬂuence of the region and other covariates on
the survival experience of children with cancer in three groups:
all types of cancer, ALL, and CNS tumors malignancies. The
multivariate model including ‘‘all types of cancer’’ showed that
children from all regions when compared with the central region
had a signiﬁcant risk of death; the east and south-southeast
regions had the highest risk (hazard ratio 3.0; 95% CI: 2.3–3.9;
2.4, 95% CI: 2.0–2.8, respectively). Children whose age at diag-
nosis was less than 1 year or 15–19 years of age, those with
illiterate mothers, at high risk, had relapse, or had AE grades
2–3 and 4–5, were at higher risk of death. Analysis of diagnosis
demonstrated that patients with CNS tumors and bone tumors
were at higher risk of death than individuals diagnosed with other
cancers. The multivariate analysis for leukemia demonstrated
similar risks; although, females with hematological malignancies
had lower probability of death than boys (HR 0.9; 95% CI: 0.7–
1.0, P ¼ 0.055). The analysis of CNS tumors showed higher risk
of death in children in the east region (HR 2.6; 95% CI: 1.0–6.2),
northwest region (HR 2.5; 95% CI: 1.3–5.0), and the south-south-
east (HR 2.2; 95% CI: 1.2–4.1).
DISCUSSION
This study demonstrates the progress of FPGC in increasing
coverage for cancer care for children and adolescents that receive
ﬁnancial support and a wide variability in survival experiences of
the new cases funded by this program across the regions in the
country. After 4 years approximately 50% of expected number of
pediatric cancer cases (without social security) had being funded
to receive healthcare. This demonstrates increase in FPGC cover-
age, but our data do not support if there was an increase in supply
for cancer care (i.e., the number of pediatric cancer units). Access
for cancer care does not rely only on monetary resources, it also
requires availability of appropriate services [34]; yet, is reason-
able to assume that hospitals increased their capability to be
certiﬁed and receive FPGC funds. Furthermore, the actual number
of children treated may not have increased, although the cost of
care shifted from the parents or other funders to FPGC, thus
reducing the number of out-of-pocket payers.
The percentage of abandonment of treatment was lower than
reported in other studies. In Latin American countries, abandon-
ment rates range from 10% to 24%, even in cases where treatment
was ﬁnancially covered [35]. Various factors are associated with
TABLE III. Inﬂuence of Geographical Region and Other Covariates on Survival of Children With Cancer Covered by the Fund for
Protection Against Catastrophic Expenditures
All types of cancer Leukemia CNS tumors
Hazard ratio 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
Geographical region
West 1.4 1.1–1.7 1.4 1.1–1.8 1.1 0.5–2.5
Northwest 1.8 1.4–2.4 1.5 1.0–2.3 2.5 1.3–5.0
East 3.0 2.3–3.9 2.7 1.8–4.1 2.6 1.0–6.2
South-southeast 2.4 2.0–2.8 2.6 2.0–3.2 2.2 1.2–4.1
Age of diagnosis
<1 year 1.7 1.2–2.2 2.2 1.5–3.2 1.1 0.3–3.3
5–9 years 1.1 0.9–1.3 1.2 0.9–1.6 0.9 0.5–1.6
10–14 years 1.2 0.9–1.5 1.4 1.1–1.8 0.6 0.3–1.3
15–19 years 1.5 1.2–1.9 1.8 1.3–2.6 1.9 0.6–6.2
Mother schooling
Illiterate 1.7 1.1–2.6 1.8 1.0–3.2 1.5 0.4–4.5
Primary school 1.3 0.9–1.9 1.4 0.8–2.4 1.4 0.5–3.6
Secondary school 1.2 0.8–1.8 1.3 0.7–2.3 1.2 0.4–3.2
Preparatory school 1.1 0.8–1.7 1.3 0.7–2.4 1.2 0.4–3.8
High risk 1.3 1.2–1.6 1.4 1.1–1.8 0.9 0.4–1.4
Treatment relapse 1.2 1.0–1.4 1.3 1.0–1.7 1.1 0.5–2.2
Adverse events
Grades 2–3 1.4 1.2–1.7 1.4 1.1–1.8 0.9 0.6–1.5
Grades 4–5 4.9 4.1–5.9 5.1 4.0–6.5 2.3 0.9–5.9
Female sex 0.9 0.8–1.0 0.9 0.7–1.0 1.3 0.8–2.1
Type of cancer
Leukemia 1.1 0.8–1.4
CNS tumors 2.0 1.4–2.7
Retinoblastoma 1.4 0.9–2.3
Renal tumors 1.3 0.8–2.0
Malignant bone tumors 1.8 1.3–2.5
Others 1.3 0.9–1.7
Bold values indicate statistically signiﬁcant results (P < 0.05) in the Cox proportional hazards model.
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ence to treatment and increased delay of appointments and to buy
medications [36]. The overall abandonment rate in this study was
6.2%, although in the east region it reached 20.2%. Further stud-
ies would be beneﬁcial to understand better the problem and
develop interventions to improve adherence.
The prevalence of the various types of childhood cancer in this
study was similar to the pattern in Latin America where acute
leukemia is the most prevalent, followed by lymphomas and CNS
tumors [37]. Nonetheless, these results should be taken with
caution and not be interpreted as representative of the incidence
of cancer in this population. The proportional number of ALL was
probably related to the fact that this was the ﬁrst condition that
FPGC ﬁnanced and the other types of cancer were included
gradually to the program. The condition of the patient at diagnosis
was also noteworthy; 51% of patients were at high risk when
diagnosed. These data suggest that these children do not have
access to diagnostic services at early stages of the condition
[38]. The survival rates of Mexican children were sub-optimal
when compared with developed countries. Overall survival analy-
sis should include patients with a 5-year follow up period. How-
ever, the analysis was carried out with a 3-year follow up period,
as this is the length of time that the fund to care for children with
cancer has been in place. The survival rate for ALL was 50% at
36 months follow up. This group included standard and high-risk
leukemia. In the United States, the Surveillance Epidemiology
and End Results (SEER) [39] data report 5-year survival of
77% and St Jude Children’s Research Hospital data reports 5-
year survival data >90% [40]. This report includes patients with
high-risk ALL from 1983 with a 73% prediction of cure [41]. The
survival rate of AML was 30.5%. The current treatment results in
a 60% survival rate for AML patients [42].
Regarding Hodgkin lymphoma, the survival rate was 74.5% at
36 months. SEER reported a 96% 5-year survival in adolescents
[43,44]. Non-Hodgkin lymphoma had a survival rate of 40.1% at
36 months. It is difﬁcult to make comparisons with this type of
malignancy as various treatments are available, and a minimum of
three histological types exists: Burkitt, anaplastic, and lympho-
blastic lymphomas. However, a report that included all histologi-
cal types estimated a 76.2% survival rate in adolescence and an
81% survival rate in childhood [45].
Survival time varied among the regions. The east and south-
southeast regions had the poorest outcomes. Several aspects may
inﬂuence the differences observed in survival rates among
regions. The policy of funding all childhood cancer treatments
is relatively new and entered gradually in the country. Therefore,
it will require more time and additional resources to achieve
reasonable outcomes. Further investigation and follow-up is re-
quired. For example, analyzing the health production function and
survival rates of individual hospitals or among children with and
without social security should help to determine benchmarks
within the Mexican health sector.
A weakness of the study is the use of the age-standardized
incidence rate for all types of cancer for cases aged 0–14 to
estimate the number of expected cases for all types of cancer
for children aged 0–19. Since the inception of the study we
searched for the age-standardized incidence rate for children 0–
14 and for adolescents 15–19 in Mexico; however, only the ﬁgure
for the age group 0–14 years was available. In the US the inci-
dence rates for 0–14 and for adolescents are 151 and 210 per
million, respectively [46]. These rates appear to be higher than the
ones reported for Mexican children; if such ﬁgures were used, the
incidence rate for the 15–19 years group would be overestimated.
Though the incidence rate is higher among adolescents, we did
not have an educated guess for Mexican population; therefore, we
decided to use the same ﬁgure, although, the need exist to have
these ﬁgures and the potential effect of underestimating the cov-
erage for the group of adolescents.
This study analyzed the period during which funds for cancer
for children afﬁliated with FPGC have been in existence. In-depth
analysis of the adherence to treatment protocols was not carried
out as all MoH hospitals had standardized therapeutic protocols.
However, severe AE (13.8%) were frequent and this requires
additional analysis. It is expected that patients suffer severe AE;
however, if they receive inadequate treatment, this can be the
cause of death.
From 2006 to 2009, FPGC has increased coverage of cancer
cases that receive ﬁnancial support from 3.3% to 55.3%. Howev-
er, survival rates were different throughout the country. Using this
report as a baseline, it will be imperative to continue to evaluate
the effectiveness of this policy to increase access and identify
opportunities to reduce the regional disparities in survival. The
ﬁndings could be used to build on the knowledge derived from
low and middle-income country’s experiences concerning the
advancement of policies to improve cancer care for children
without medical insurance.
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